Stayble Therapeutics

Stayble Therapeutics AB is a Swedish clinical-stage biopharmaceutical company based in Gothenburg. It develops STA363, an injectable treatment concept for pain caused by herniated disc, with the aim of addressing the underlying cause of symptoms rather than only providing temporary relief.

— Stayble Therapeutics
%
Drug candidate development100% Development of STA363 as a treatment for pain caused by herniated disc.
Clinical research and trials0% Clinical study work to test safety, efficacy, and dosing of the candidate.
Licensing and commercialization rights0% Potential future out-licensing or partnering of the treatment concept.

Stayble does not appear to sell a commercial product yet; its near-term counterparties are clinical trial participants,...

  • Clinical trial participantsprimary

    Patients enrolled to evaluate STA363 safety and efficacy in disc-related pain.

  • Clinical investigators and trial sitesprimary

    Hospitals and research centers that administer the study protocol and collect data.

  • Potential licensing partnerssecondary

    Pharmaceutical or biotech companies that may acquire rights to develop or commercialize STA363.

  • Future treating physicians and clinicsemerging

    Healthcare providers that would prescribe or administer the treatment if approved.

Stayble is headquartered in Gothenburg, Sweden, and its corporate and development activities are anchored there...

  • •Headquartered in Gothenburg, Sweden
  • •Corporate and development functions are based in Sweden
  • •No disclosed commercial revenue geography in the provided reports
  • •Clinical development depends on external trial locations and partners

Stayble’s strategy is centered on advancing STA363 through clinical development and building evidence that the...

01
Advance clinical development of STA363short-term

Clinical data is the main value driver for a pre-commercial biotech company.

02
Differentiate with a one-time injection conceptmedium-term

A simple treatment profile can improve adoption and partnering appeal.

03
Prepare for partnering or commercializationmedium-term

External partners may be needed to fund late-stage development and market access.

Stayble is exposed to the classic risks of a clinical-stage biotech company: funding needs, uncertain trial outcomes,...

critical

Financing risk

The company has no approved treatment generating sales and must fund ongoing development.

Scope
Clinical development and corporate overhead
Materiality
high
high

Clinical trial risk

Drug development depends on proving safety and efficacy in human studies.

Scope
STA363 development program
Materiality
high
high

Partner dependency risk

Development and future commercialization may rely on external collaborators.

Scope
Clinical operations, production, licensing
Materiality
medium
high

Regulatory approval risk

Even promising clinical data may not translate into marketing authorization.

Scope
Future commercialization pathway
Materiality
high
Research and development expense recognition
Affects operating result and comparability across periods
Accruals for clinical trial and advisory costs
Can shift expenses between quarters
Going concern and liquidity assumptions
Affects disclosure and valuation of the business
Impairment and capitalization judgments
Can materially affect balance sheet and earnings

Aquestive Therapeutics, Inc.

AQST · Pharmaceutical Preparations

Ceribell, Inc.

CBLL · Electromedical & Electrotherapeutic Apparatus

Anebulo Pharmaceuticals, Inc.

ANEB · Pharmaceutical Preparations

RETRACTABLE TECHNOLOGIES INC

RVP · Surgical & Medical Instruments & Apparatus

TherapeuticsMD, Inc.

TXMD · Pharmaceutical Preparations

TACTILE SYSTEMS TECHNOLOGY INC

TCMD · Surgical & Medical Instruments & Apparatus

: 11/08/2026